

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM405242

| | | | |
|-----------------------------------|---------------------------------|--|-------------------------|
| SUBMISSION TYPE: | NEW ASSIGNMENT | | |
| NATURE OF CONVEYANCE: | SECURITY INTEREST | | |
| CONVEYING PARTY DATA | | | |
| Name | Formerly | Execution Date | Entity Type |
| CHROMADDEX, INC. | | 11/04/2016 | Corporation: CALIFORNIA |
| RECEIVING PARTY DATA | | | |
| Name: | Western Alliance Bank | | |
| Street Address: | 55 Almaden Boulevard, Suite 100 | | |
| Internal Address: | Attn: Justin Vogel | | |
| City: | SAN JOSE | | |
| State/Country: | CALIFORNIA | | |
| Postal Code: | 95113 | | |
| Entity Type: | Corporation: ARIZONA | | |
| PROPERTY NUMBERS Total: 22 | | | |
| Property Type | Number | Word Mark | |
| Serial Number: | 87079907 | ANTHORIGIN | |
| Serial Number: | 86862053 | NR | |
| Serial Number: | 86616799 | IMMULINA | |
| Serial Number: | 86761654 | NIAGEN ESSENTIAL FOR LIFE | |
| Serial Number: | 86756127 | ESSENTIAL FOR LIFE | |
| Serial Number: | 86588333 | C | |
| Serial Number: | 85932490 | NIAGEN | |
| Serial Number: | 85482454 | MEMORYBLU | |
| Serial Number: | 85306669 | BLU2GO | |
| Serial Number: | 85306177 | HEARTBLU | |
| Serial Number: | 85306174 | ETERNALBLU | |
| Serial Number: | 85306170 | TRIMBLU | |
| Serial Number: | 85306166 | THE FUSION OF BLUEBERRIES AND SCIENCE | |
| Serial Number: | 85306158 | BLUSCIENCE THE FUSION OF BLUEBERRIES AND | |
| Serial Number: | 85306142 | BLUSCIENCE | |
| Serial Number: | 85857505 | PUREENERGY | |
| Serial Number: | 85798937 | NUTRAGAC | |
| Serial Number: | 85685203 | PTEROBERRY | |

CH \$565.00 87079907

| Property Type | Number | Word Mark |
|----------------|----------|-----------|
| Serial Number: | 85685195 | PROC3G |
| Serial Number: | 85254515 | |
| Serial Number: | 77939875 | PTEROPURE |
| Serial Number: | 77939870 | CHROMADEX |

CORRESPONDENCE DATA

Fax Number: 8586385130

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 858-677-1400

Email: susan.reynholds@dlapiper.com

Correspondent Name: DLA Piper LLP (US)

Address Line 1: 4365 Executive Drive, Suite 1100

Address Line 4: San Diego, CALIFORNIA 92121

| | |
|---------------------------|-----------------|
| NAME OF SUBMITTER: | Troy Zander |
| SIGNATURE: | /s/ Troy Zander |
| DATE SIGNED: | 11/11/2016 |

Total Attachments: 18

- source=ChromaDex IPSA#page1.tif
- source=ChromaDex IPSA#page2.tif
- source=ChromaDex IPSA#page3.tif
- source=ChromaDex IPSA#page4.tif
- source=ChromaDex IPSA#page5.tif
- source=ChromaDex IPSA#page6.tif
- source=ChromaDex IPSA#page7.tif
- source=ChromaDex IPSA#page8.tif
- source=ChromaDex IPSA#page9.tif
- source=ChromaDex IPSA#page10.tif
- source=ChromaDex IPSA#page11.tif
- source=ChromaDex IPSA#page12.tif
- source=ChromaDex IPSA#page13.tif
- source=ChromaDex IPSA#page14.tif
- source=ChromaDex IPSA#page15.tif
- source=ChromaDex IPSA#page16.tif
- source=ChromaDex IPSA#page17.tif
- source=ChromaDex IPSA#page18.tif

INTELLECTUAL PROPERTY SECURITY AGREEMENT

This INTELLECTUAL PROPERTY SECURITY AGREEMENT, dated as of ~~October~~ ^{November 17, 2016} 2016, (the "Agreement") between WESTERN ALLIANCE BANK, an Arizona corporation ("Lender") and CHROMADEX, INC., a California corporation ("Grantor") is made with reference to the Business Financing Agreement, dated as of ~~October~~ ^{November 17, 2016} 2016 (as amended from time to time, the "Financing Agreement"), among Lender, Grantor, CHROMADEX CORPORATION, CHROMADEX ANALYTICS, INC. and SPHERIX CONSULTING, INC. Terms not otherwise defined herein are defined as set forth in the Financing Agreement. ^{November 17, 2016}

For good and valuable consideration, receipt of which is hereby acknowledged, Grantor hereby covenants and agrees as follows:

To secure the Obligations under the Financing Agreement, Grantor grants to Lender a security interest in all right, title, and interest of Grantor in any of the following, whether now existing or hereafter acquired or created in any and all of the following property (collectively, the "Intellectual Property Collateral"):

(a) copyright rights, copyright applications, copyright registrations and like protections in each work or authorship and derivative work thereof, whether published or unpublished and whether or not the same also constitutes a trade secret, now or hereafter existing, created, acquired or held (collectively, the "Copyrights"), including the Copyrights described in Exhibit A;

(b) trademark and servicemark rights, whether registered or not, applications to register and registrations of the same and like protections, and the entire goodwill of the business of Borrower connected with and symbolized by such trademarks (collectively, the "Trademarks"), including the Trademarks described in Exhibit B;

(c) patents, patent applications and like protections including without limitation improvements, divisions, continuations, renewals, reissues, extensions and continuations-in-part of the same (collectively, the "Patents"), including the Patents described in Exhibit C;

(d) mask work or similar rights available for the protection of semiconductor chips or other products (collectively, the "Mask Works");

(e) trade secrets, and any and all intellectual property rights in computer software and computer software products;

(f) design rights;

(g) claims for damages by way of past, present and future infringement of any of the rights included above, with the right, but not the obligation, to sue for and collect such damages for said use or infringement of the intellectual property rights identified above;

(h) licenses or other rights to use any of the Copyrights, Patents, Trademarks, or Mask Works, and all license fees and royalties arising from such use to the extent permitted by such license or rights;

(i) amendments, renewals and extensions of any of the Copyrights, Trademarks, Patents, or Mask Works; and

(j) proceeds and products of the foregoing, including without limitation all payments under insurance or any indemnity or warranty payable in respect of any of the foregoing.

The rights and remedies of Lender with respect to the security interests granted hereunder are in addition to those set forth in the Financing Agreement, and those which are now or hereafter available to Lender as a matter of law or equity. Each right, power and remedy of Lender provided for herein or in the Financing Agreement, or now or hereafter existing at law or in equity shall be cumulative and concurrent and shall be in addition to every right, power or remedy provided for herein, and the exercise by Lender of any one or more of such rights, powers or remedies does not preclude the simultaneous or later exercise by Lender of any other rights, powers or remedies.

IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

GRANTOR:

CHROMADEX, INC.

By: [Signature]

Name: Thomas C Varva

Title: CFO

Address for Notices:

Attn: Tom Varvaro, Chief Financial Officer
10005 Muirlands Boulevard, Suite G
Irvine, CA 92618
Fax: (949) 356-1601

LENDER:

WESTERN ALLIANCE BANK, an Arizona corporation

By: [Signature]

Name: Grant Simon

Title: AVP

Address for Notices:

Attn: Justin Vogel
55 Almaden Blvd, Ste 100
San Jose, CA 95113
Tel: (408) 423-8500
Fax: (408) 686-8542

[Signature Page to Intellectual Property Security Agreement]



EXHIBIT A
COPYRIGHTS


Please Check if No Copyrights Exist

| <u>Type of Work</u> | <u>Title</u> | <u>International Standard Serial Number (ISSN)</u> | <u>Registration Number</u> | <u>Filing Date</u> | <u>Preregistered?</u> |
|---------------------|---|--|--------------------------------|------------------------|-----------------------|
| | ChromalDex 99% Pure Curcumin | | TXU001727021 | 1/4/11 | |
| | ChromalDex Phytochemicals and Services 2011 Catalog | | TXU001745307 | 1/3/11 | |
| | The effects of Pterostilbene on Cholesterol | | TXU001779804 | 11/8/11 | |
| | The effects of Pterostilbene on Oxidative Stress and Cognitive Function | | TXU00177346 | 10/31/11 | |
| | pTeroPure Brochure | | TXU001746130 | 2/14/11 | |
| | pTeroPure Pterostilbene. The Next Generation Resveratrol | | TXU001745172 | 1/14/11 | |
| | Vitamin K2 Products and Services | | TXU001790906 | 1/4/11 | |

EXHIBIT B
TRADEMARKS

Please Check if No Trademarks Exist

| Mark / Title | U.S. Serial Number | U.S. Registration Number | UPTO Reference Number | Filing Date |
|---|--------------------|--------------------------|-----------------------|-------------|
| ANTHORIGIN | 87079907 | | Classes 1 & 5 | 6/22/16 |
| NR | 88862053 | | Classes 1 & 5 | 12/30/15 |
| IMMULINA | 85616799 | | Classes 1 & 5 | 3/29/16 |
| NIAGEN ESSENTIAL FOR LIFE | 86761654 | | Class 5 | 9/18/15 |
| ESSENTIAL FOR LIFE | 86756127 | | Class 1 | 2/9/16 |
|  | 86588333 | 4855009 | Classes 1, 5 & 42 | 4/6/15 |
| NIAGEN | 85932490 | 4606519 | Classes 1 & 5 | 5/13/15 |
| MEMORYBLU | 85482454 | 4302406 | Class 5 | 11/29/11 |
| BLU2GO | 85306669 | 4169079 | Class 5 | 4/27/11 |
| HEARTBLU | 85306177 | 4172760 | Class 5 | 4/27/11 |
| ETERNALBLU | 85306174 | 4189078 | Class 5 | 4/27/11 |
| TRIMBLU | 85306170 | 4172758 | Class 5 | 4/27/11 |
| THE FUSION OF BLUEBERRIES AND SCIENCE | 85306166 | 4242836 | Class 5 | 4/27/11 |
|  BioScience | 85306158 | 4222710 | Class 5 | 4/27/11 |
| BLUSCIENCE | 85306142 | 4226687 | Class 5 | 4/27/11 |
| PUREENERGY | 85857505 | 4512267 | Class 1 | 2/22/13 |
| NUTRAGAC | 85798937 | 4530458 | Class 1 | 12/10/12 |

| | | | | |
|---|----------|---------|----------------|---------|
| pTeroBerry | 85685203 | 4538512 | Class 1 | 7/24/12 |
| ProC3G | 85685195 | 4468837 | Class 1 | 7/24/12 |
|  | 85254515 | 4210890 | Classes 1 & 42 | 3/1/11 |
| pTeroPure | 77636075 | 3932510 | Class 1 | 2/19/10 |
| CHROMADEX | 77929870 | 3999088 | Classes 1 & 42 | 2/19/10 |

WESTLAW 1003682.2
365117-000281

EXHIBIT C

PATENTS

Please Check if No Patents Exist

| <u>Title</u> | <u>Patent Number</u> | <u>Application Serial Number</u> | <u>Issued or Published?</u> | <u>Issue Date</u> |
|---|----------------------|----------------------------------|-----------------------------|-------------------|
| Yeast strain and method for using the same to produce nicotinamide riboside | 8114626 | | YES | 2/14/2012 |
| Nicotinamide riboside kinase compositions and methods for using the same | 8197807 | | YES | 6/12/2012 |
| Nicotinamide riboside kinase compositions and methods for using the same | 8383086 | | YES | 2/28/2013 |
| Methods and compositions for treating neuropathies | 7776326 | | YES | 8/17/2010 |
| Yeast strain and method for using the same to produce nicotinamide riboside | | US 11/542832 | NO | |
| Yeast strain and method for using the same to produce nicotinamide riboside | | US 13/260392 | NO | |
| Yeast strain and method for using the same to produce nicotinamide riboside | | US 20120164270 (A1) | NO | |
| Yeast strain and method for using | | PCT US2010/027792 | NO | |

WESTLAW 1852682 &
351157-000261

6

| | | | | |
|---|--|------------------|----|--|
| the same to produce nicotinamide riboside | | | | |
| Yeast strain and method for using the same to produce nicotinamide riboside | | WO 2010111111 A1 | NO | |
| Methods and compositions for treating neuropathies | | US 60/886854 | NO | |
| Methods and compositions for treating neuropathies | | US 12/524718 | NO | |
| Methods and compositions for treating neuropathies | | US 2010047177 A1 | NO | |
| Methods and compositions for treating neuropathies | | PCT | NO | |
| Methods and compositions for treating neuropathies | | WO 2008091710 A2 | NO | |
| Methods and compositions for treating neuropathies | | CA 2676606 | NO | |
| Methods and compositions for treating neuropathies | | MX 20090008022 | NO | |
| Nicotinamide riboside kinase compositions and methods for using the same | | AU 2006238858 A2 | NO | |
| Nicotinamide riboside kinase compositions and methods for using the same | | CA 2609633 | NO | |
| Methods and compositions for treating neuropathies | | US 60/577233 | NO | |
| Methods and compositions for treating neuropathies | | US 60/641330 | NO | |

WESTL 27 1662682 2
355157-000251

| | | | | |
|--|-----------|--------------------|-----|-----------|
| neuropathies Methods and compositions for treating neuropathies | | PCT 2005/019524 | NO | |
| Methods and compositions for treating neuropathies | | WO 2006001982 A2 | NO | |
| Methods and compositions for treating neuropathies | | ZL 200580018114 8 | NO | |
| Methods and compositions for treating neuropathies | | CN 1964627 | NO | |
| Methods and compositions for treating neuropathies | | US 11/144358 | NO | |
| Methods and compositions for treating neuropathies | | US 12/780722 | NO | |
| Methods and compositions for treating neuropathies | | US 20100272702 A1 | NO | |
| Methods and compositions for treating neuropathies | | EP 20050790283 | NO | |
| Methods and compositions for treating neuropathies | | EP 1755391 A2 | NO | |
| Pterostilbene as an agonist for the peroxisome proliferator-activated receptor alpha isoform | 8133917 | | YES | 3/13/2012 |
| Pterostilbene as an agonist for the peroxisome proliferator-activated receptor alpha isoform | 8252845 | | YES | 2/28/2013 |
| Anxiolytic Effects of Pterostilbene | 9,439,875 | US 13/105470 | YES | 09/13/16 |
| | | PCT PCT/US12/37325 | NO | |

| | | | | |
|--|------------|---|-----|-----------|
| | | AU 2012253479 BRAZIL 112013028776-4 CANADA 2839309 CHINA 2012800221785 HONG KONG 14107876 8 EP 12 781 700 5 JAPAN 2014-510467 | | |
| Use of pterostilbene as medicament for prevention and/or treatment of skin diseases, damages or injuries or as cosmetic | | KOR 10-2012-7013257 | NO | |
| Use of pterostilbene as medicament for prevention and/or treatment of skin diseases, damages or injuries or as cosmetic. | | MX 2012/006013 | NO | |
| Use of pterostilbene as medicament for prevention and/or treatment of skin diseases, damages or injuries or as cosmetic. | | RUS 2012122241 | NO | |
| Use of pterostilbene as medicament for prevention and/or treatment of skin diseases, damages or injuries or as cosmetic. | | US 13/504056 | NO | |
| Combine use of pterostilbene and quercetin for the production of cancer treatment medicaments. | US 8227510 | | YES | 7/24/2012 |

| | | | | |
|--|---------------|--------------------|-----|-----------|
| Combine use of pterostilbene and quercetin for the production of cancer treatment medicaments | EU 5774387.4 | | YES | 3/18/2009 |
| Use of pterostilbene as medicament for prevention and/or treatment of skin diseases, damages or injuries or as cosmetic | EU 10775793.2 | | YES | 7/24/2013 |
| Use of pterostilbene as medicament for prevention and/or treatment of skin diseases, damages or injuries or as cosmeting | | CA 2778181 | NO | |
| Use of pterostilbene as medicament for prevention and/or treatment of skin diseases, damages or injuries or as cosmetic | | CHN 201080048865.5 | NO | |
| Use of pterostilbene as medicament for prevention and/or treatment of skin diseases, damages or injuries or as cosmetic | | ISRL 219218 | NO | |
| Use of pterostilbene as medicament for prevention and/or treatment of skin diseases, damages or injuries or as cosmetic | | JPN 2012-535862 | NO | |
| Method for Inducing UDP-Glucuronosyltransferase Activity Using Pterostilbene | B,841,350 | | YES | 9/23/2014 |
| Method for Inducing UDP-Glucuronosyltransferase Activity Using | | US 14/493,058 | NO | |

| | | | | |
|--|--|-----------------------|----|--|
| Pterostilbene | | | | |
| Method for Inducing UDP-Glucuronosyltransferase Activity Using Pterostilbene | | PCT US2012/064993 | NO | |
| Method for Inducing UDP-Glucuronosyltransferase Activity Using Pterostilbene | | AU 2012 379655 | NO | |
| Method for Inducing UDP-Glucuronosyltransferase Activity Using Pterostilbene | | BR BR11 2014 027646 3 | NO | |
| Method for Inducing UDP-Glucuronosyltransferase Activity Using Pterostilbene | | CA 2,872,623 | NO | |
| Method for Inducing UDP-Glucuronosyltransferase Activity Using Pterostilbene | | CN 201280074486.2 | NO | |
| Method for inducing UDP-Glucuronosyltransferase Activity Using Pterostilbene | | EP 12876092.3 | NO | |
| Method for Inducing UDP-Glucuronosyltransferase Activity Using Pterostilbene | | IN 9990/DELNP/2014 | NO | |
| Method for Inducing UDP-Glucuronosyltransferase Activity Using Pterostilbene | | JP 2015-511433 | NO | |
| Method for Inducing UDP-Glucuronosyltransferase Activity Using Pterostilbene | | KR 10-2014-7034337 | NO | |
| Method for Inducing UDP-Glucuronosyltransferase Activity Using | | MX MX/a/2014/013503 | NO | |

| | | | | |
|--|---------|---|-----|-----------|
| Pterostilbene | | | | |
| Method for Inducing UDP-Glucuronosyltransferase Activity Using Pterostilbene | | NZ 701543 | NO | |
| Method for Inducing UDP-Glucuronosyltransferase Activity Using Pterostilbene | | ZA 2014/08893 | YES | 8/31/16 |
| Prevention of UV-induced hyperplasia and DNA damage in skin by Pterostilbene | | US 62/046,065 | NO | |
| Prevention of UV-induced loss of barrier function in skin by Pterostilbene | | US 62/046,068 | NO | |
| Use of Polyphenols in the Treatment of Cancer | | US 61/249188 | NO | |
| Anti-Obesity Effect Of Pterostilbene | | US 13/463,442 | NO | |
| | | PCT PCT/US2013/037962 EP 13784230 B | | |
| Potent Immunostimulants from Microalgae | 7205284 | | YES | 4/17/2007 |
| NICOTINAMIDE RIBOSIDE COMPOSITIONS FOR TOPICAL USE IN TREATING SKIN CONDITIONS | | US 61/897713 CHINESE PATENT APPL NO 201480071722.4 | NO | |
| NR Compositions for Topical Use | | PCT US2014/063260 | NO | |
| NR Compositions for Topical Use | | AU 2014342185 | NO | |
| NR Compositions for Topical Use | | BR 11 2016 009349 6 | NO | |
| NR Compositions for Topical Use | | CA 2 928,656 | NO | |

| | | | | |
|--|--|--------------------|----|--|
| NR Compositions for Topical Use | | CN 201480071722.4 | NO | |
| NR Compositions for Topical Use | | EP 14857903.0 | NO | |
| NR Compositions for Topical Use | | IN 201617016594 | NO | |
| NR Compositions for Topical Use | | JP 2016-525337 | NO | |
| NR Compositions for Topical Use | | KR 10-2016-7014302 | NO | |
| NR Compositions for Topical Use | | MX/a/2016/005574 | NO | |
| NR Compositions for Topical Use | | NZ 719328 | NO | |
| NR Compositions for Topical Use | | ZA 2016/03314 | NO | |
| NR Compositions for Topical Use | | US 15/033,285 | NO | |
| Topical Ptero/Hyperplasia & DNA Damage | | US 14/845,171 | NO | |
| Topical Ptero/Hyperplasia & DNA Damage | | PCT US2015/484329 | NO | |
| Topical Ptero/Barrier Function | | US 14/845,173 | NO | |
| Topical Ptero/Barrier Function | | PCT US2015/484228 | NO | |
| NRH/NARH TA for skin damage | | US 15/072,121 | NO | |
| NRH/NARH TA for skin damage | | PCT US2016/22682 | NO | |
| NR Derivatives as NAD Precursors in Fermentation | | US 62/255,636 | NO | |
| NR/NAR infant formula | | US 62/322,460 | NO | |
| NAR/NARH/NRH as NAD Precursors | | US 62/326,264 | NO | |
| Potent Immunostimulants | | AU 2001273330 | NO | |

| | | | | |
|---|-------------------|------------------|-----|------------|
| from Microalgae Potent Immunostimulants from Microalgae | | CA 2412600 | NO | |
| Potent Immunostimulants from Microalgae | | FR 1301191 | NO | |
| Potent Immunostimulants from Microalgae | | GER 60115654 4 | NO | |
| Potent Immunostimulants from Microalgae | | NL 1301191 | NO | |
| Potent Immunostimulants from Microalgae | | SK 1008314080000 | NO | |
| Potent Immunostimulants from Microalgae | | GB 1301191 | NO | |
| Potent Immunostimulants from Microalgae | | MX 254542 | NO | |
| Potent Immunostimulants from Microalgae | | JPN 2002-508454 | NO | |
| Extracted whole corn kernels and improved processed and processable corn produced thereby | 8945653 | | YES | 2/3/2015 |
| ANGIOLYTIC EFFECT OF PTEROSTILBENE | 9,439,875 | | YES | 09/13/20 |
| Method to Ameliorate Oxidative Stress and Improve Working Memory via Pterostilbene Administration | 8,809,400 | | YES | 08/19/2014 |
| Method to Ameliorate Oxidative Stress and Improve Working Memory via Pterostilbene Administration | 9,026,887 | | YES | 05/12/15 |
| Method to Ameliorate Oxidative Stress and Improve Working Memory via Pterostilbene | CANADA 2696861 | | YES | 03/07/10 |

WEST:271662682.2
355157-000281

| | | | | |
|---|------------------------------|--|-----|------------|
| Administration | | | | |
| Method to Ameliorate Oxidative Stress and Improve Working Memory via Pterostilbene Administration | FRANCE 2200597 | | YES | 11/12/14 |
| Method to Ameliorate Oxidative Stress and Improve Working Memory via Pterostilbene Administration | GERMANY 60 2008 036 342 7 | | YES | 11/12/14 |
| Method to Ameliorate Oxidative Stress and Improve Working Memory via Pterostilbene Administration | GREAT BRITIAN 2200597 | | YES | 11/12/14 |
| Method to Ameliorate Oxidative Stress and Improve Working Memory via Pterostilbene Administration | ITALY 2200597 | | YES | 11/12/14 |
| Method to Ameliorate Oxidative Stress and Improve Working Memory via Pterostilbene Administration | NETHERLANDS 2200597 | | YES | 11/12/14 |
| Method to Ameliorate Oxidative Stress and Improve Working Memory via Pterostilbene Administration | SPAIN 2200597 | | YES | 11/12/14 |
| Method to Ameliorate Oxidative Stress and Improve Working Memory via Pterostilbene Administration | SWITZERLAND 2200597 | | YES | 11/12/14 |
| Method to | JAPAN | | YES | 09/05/2014 |

| | | | | |
|---|---------|---|----|--|
| Ameliorate Oxidative Stress and Improve Working Memory via Pterostilbene Administration | 5608082 | | | |
| Method to Ameliorate Oxidative Stress and Improve Working Memory via Pterostilbene Administration | | CHINA 200880110318.8 20121021008.8 | NO | |
| Method to Ameliorate Oxidative Stress and Improve Working Memory via Pterostilbene Administration | | HONG KONG 11101728.4 13112566.4 | NO | |
| Method to Ameliorate Oxidative Stress and Improve Working Memory via Pterostilbene Administration | | EP 08799127.9 | NO | |
| Methods of preparing nicotinamide riboside and derivatives thereof | | European Application No. 14744082.0 Hong Kong Application No. 16106843.8 Canadian Patent Application No. 2,918,955 UK Patent Application No. 1313465.5 Australian Patent Application No. 2014238629 | NO | |
| B-VITAMIN CONJUGATES OF NICOTINAMIDE OR NICOTINATE RIBOSIDES | | U.S. Provisional Patent Appl. No. 62/309,273 | NO | |
| USE OF NICOTINAMIDE RIBOSIDE, NICOTINIC ACID RIBOSIDE, AND | | 62/322,460 | | |

WEST1271662682.2
355157.000261

| | | | | |
|---|-----------|-------------------|-----|----------|
| NICOTINAMIDE MONONUCLEOTIDE, REDUCED NICOTINYL COMPOUNDS AND NICOTINYL COMPOUND DERIVATIVES IN INFANT FORMULA FOR HEALTHY DEVELOPMENT | | | | |
| A key intermediate for the preparation of stilbenes | | WO/2010/010576 A2 | NO | |
| A key intermediate for the preparation of stilbenes | 8524782 | | YES | 09/03/13 |
| Pterostilbene and pvp grape juice extract combination for treatment of metabolic, vascular, and neurodegenerative disorders | | 13/712,747 | | 12/12/12 |
| Pterostilbene and curcumin combination for treatment of oxidative stress and inflammation | | 13,874,220 | | 4/30/13 |
| Method for treating non-melanoma skin cancer by inducing adp-glucuronosyl transferase activity using pterostilbene | | 14,493,058 | | 8/22/14 |
| Compounds for altering food intake in humans | 6,852,342 | | | 2/8/05 |
| Methods and compositions for detecting active components using bioluminescent bacteria and thin-layer chromatography | | 11,623,620 | | 1/16/07 |
| Nicotinic acid | | 15,072,171 | | 3/16/16 |

| | | | | |
|--|--|--|--|--|
| riboside or nicotinamide riboside compositions, reduced derivatives thereof, and the use thereof to enhance skin permeation in treating skin conditions. | | | | |
|--|--|--|--|--|

WEST 271582682 2
355157-000261